Naibec Validates Efficacy of Global Pharma's Orthotopic Tumor Model

[Asia Economy Reporter Hyunseok Yoo] Naivek, a bio-specialized company with peptide fusion technology, announced on the 15th that it will expand research cooperation on drug delivery platforms not only with global pharmaceutical companies but also with pharmaceutical companies based in the UK and Europe, based on the excellent therapeutic effects verified through allograft tumor models.

Naivek has previously signed joint research and license option agreements with global pharmaceutical companies. Based on the results of the allograft tumor model and other research achievements conducted so far, it plans to proceed with license negotiations related to drug delivery platforms with the relevant global pharmaceutical companies.

A Naivek official said, "The allograft results have already been delivered to global pharmaceutical companies, and verification of anticancer effects has been completed. Discussions on follow-up research are currently ongoing," adding, "The expansion of research means broadening the indications to which the platform technology can be applied in order to apply the drug delivery platform to various pipelines."

The follow-up research currently under discussion plans to verify the efficacy of the drug delivery platform in long-term administration based on drug dosage, pharmacokinetics, safety, and safety related to the delivery vehicle. Naivek expects that through joint research with global pharmaceutical companies and after the material optimization stage, technology transfer will be possible once the drug’s safety and selectivity are proven.

In addition, Naivek is conducting material transfer and research agreements with pharmaceutical companies based in the UK and Europe. In particular, a UK-based pharmaceutical company is negotiating to verify the possibility of improving efficacy by applying Naivek’s intracellular penetration delivery platform to the bispecific antibodies it is developing. The company explained that since many global pharmaceutical companies are conducting research on bispecific antibody-based anticancer drugs, related research outcomes are highly likely to make an impact on the global pharmaceutical market.

A Naivek official said, "Although bispecific antibodies have the advantage of effectively controlling drug targets that are variously transformed inside cells, their permeability into targeted tumor cells is low, making drug development difficult," adding, "Naivek plans to conduct research aiming to enhance therapeutic effects by increasing drug delivery efficiency based on NIPEP-TPP."

He continued, "We are discussing material transfer contracts with multiple global pharmaceutical companies, including European pharmaceutical companies, regarding gene drug delivery vehicles," adding, "Since the JP Morgan Healthcare Conference, we have been urgently conducting technology introduction discussions and data transfers with many global pharmaceutical companies. We have also been negotiating business models for collaboration with pharmaceutical companies that have already completed technical verification. Since the conference, requests for technological cooperation have increased to the extent that researchers have barely had enough time to respond."

This content was produced with the assistance of AI translation services.